一项关于安非他酮缓释片与艾司西酞普兰治疗广泛性焦虑障碍的对照试验。
A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder.
作者信息
Bystritsky Alexander, Kerwin Lauren, Feusner Jamie D, Vapnik Tanya
机构信息
Department of Psychiatry, University of California, Los Angeles, CA, USA.
出版信息
Psychopharmacol Bull. 2008;41(1):46-51.
OBJECTIVE
To compare the efficacy and safety of bupropion XL (150 to 300 mg/day) with the selective serotonin reuptake inhibitor escitalopram (10 to 20 mg/day) in outpatients diagnosed with generalized anxiety disorder (GAD).
METHODS
Twenty-four participants with GAD between 18 and 64 years enrolled in a 12-week, double-blind, randomized trial. The primary efficacy measures were the Clinical Global Impression of Improvement (CGI-I) and the Hamilton Anxiety Rating Scale (HARS).
RESULTS
Bupropion XL demonstrated comparable anxiolytic efficacy to escitalopram in outpatients with GAD. Both treatments were well-tolerated.
CONCLUSION
Findings from this pilot project suggest that bupropion XL may be useful in treating GAD. These preliminary results warrant further research to explore the use of bupropion XL in the treatment of GAD.
目的
比较安非他酮缓释片（每日150至300毫克）与选择性5-羟色胺再摄取抑制剂艾司西酞普兰（每日10至20毫克）治疗广泛性焦虑症（GAD）门诊患者的疗效和安全性。
方法
24名年龄在18至64岁之间的广泛性焦虑症患者参加了一项为期12周的双盲随机试验。主要疗效指标为临床总体印象改善量表（CGI-I）和汉密尔顿焦虑量表（HARS）。
结果
在广泛性焦虑症门诊患者中，安非他酮缓释片显示出与艾司西酞普兰相当的抗焦虑疗效。两种治疗方法耐受性均良好。
结论
该试点项目的结果表明，安非他酮缓释片可能对治疗广泛性焦虑症有用。这些初步结果值得进一步研究，以探索安非他酮缓释片在广泛性焦虑症治疗中的应用。
Zotero 插件